BreakBio develops personalized immunotherapy treatments for all solid cancers using proprietary AI/ML analysis of patient-specific cancer cells. The platform identifies unique protein targets to design custom synthetic drugs that stimulate T-cell activity against tumors. This approach combines patient-specific drug manufacturing with established oncology agents to improve immune system infiltration and slow cancer growth.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer therapies often target a single antigen, which can lead to tumor escape mechanisms and limited efficacy, particularly in solid tumors. Patients with advanced or rare cancers frequently face limited treatment options with low success rates.
Solution
BreakBio Corp. is developing a personalized cancer vaccine platform designed to address a broad spectrum of solid cancers. The platform utilizes a combination of artificial intelligence (AI), machine learning (ML), and mass spectrometry to identify up to 30 unique patient-specific neoantigens from a patient's tumor cells. This data is then used to design and manufacture synthetic peptide vaccines, tailored to elicit a robust T-cell response against these multiple targets. The approach aims to overcome tumor heterogeneity and resistance mechanisms, offering a more effective therapeutic strategy for patients with advanced or difficult-to-treat solid tumors.
Target Audience
The primary target audience includes oncologists, cancer researchers, and pharmaceutical companies seeking novel immunotherapies for solid tumors, particularly those with limited treatment options.
Features
- AI/ML and mass spectrometry-driven neoantigen identification from patient tumor samples.
- Proprietary platform for the design and manufacturing of personalized peptide cancer vaccines.
- Targets multiple (up to 30) patient-specific tumor antigens to enhance therapeutic efficacy.
- Applicable to all solid cancer types, regardless of tumor mutational burden (TMB).
- Investigational New Drug (IND) approval received from the FDA for BreakVax.
- Focus on developing therapies with curative intent for advanced-stage cancers.